Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Body composition as a determinant of the therapeutic index with androgen signaling inhibition.
Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg JR, Zurita AJ, Siddiqui BA, Corn PG, Subudhi SK, Msaouel P, Koutroumpakis E, Huff CD, Aparicio A, McQuade JL, Frigo DE, Logothetis CJ. Hahn AW, et al. Among authors: gregg jr. Prostate Cancer Prostatic Dis. 2024 Jul 17. doi: 10.1038/s41391-024-00870-8. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 39019979
Body composition in recurrent prostate cancer and the role of steroidogenic genotype.
Venkatesh N, Tidwell RS, Yu Y, Aparicio A, Zurita AJ, Subudhi SK, Siddiqui BA, Mukhida SS, Gregg JR, Corn PG, Koutroumpakis E, McQuade JL, Frigo DE, Pilie PG, Huff C, Logothetis CJ, Hahn AW. Venkatesh N, et al. Among authors: gregg jr. Endocr Relat Cancer. 2024 Oct 29;31(12):e240195. doi: 10.1530/ERC-24-0195. Print 2024 Dec 1. Endocr Relat Cancer. 2024. PMID: 39324992
Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance.
Gregg JR, Newcomb L, Wu R, Dennison J, Davis JW, Pettaway C, Pisters L, Ward JF, Chapin BF, Chéry L, Urkmez A, Fang AM, Higgason N, Troncoso P, Daniel CR, Logothetis C, Thompson TC, Hahn AW, Liu M, Zheng Y, Lin DW, Hanash S, Irajizad E, Fahrmann J. Gregg JR, et al. Biomark Res. 2024 Nov 9;12(1):134. doi: 10.1186/s40364-024-00678-7. Biomark Res. 2024. PMID: 39522029 Free PMC article.
Whole-body MRI for staging prostate cancer: a narrative review.
Fang AM, Gregg JR, Pettaway C, Ma J, Szklaruk J, Bathala TK, Surasi DSS, Chapin BF. Fang AM, et al. Among authors: gregg jr. BJU Int. 2025 Jan;135(1):13-21. doi: 10.1111/bju.16514. Epub 2024 Sep 22. BJU Int. 2025. PMID: 39308142 Review.
A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates.
Hahn AW, Manyam GC, Chapin BF, Zhang M, Yu Y, Pettaway CA, Chery L, Pisters LL, Ward JF, Gregg JR, Papadopoulos J, Kamat AM, Lozano M, Hoang A, Broom B, Wang X, Huff CD, Logothetis CJ, Troncoso P, Pilié PG, Davis JW. Hahn AW, et al. Among authors: gregg jr. BJU Int. 2024 Sep;134(3):449-458. doi: 10.1111/bju.16414. Epub 2024 Jun 4. BJU Int. 2024. PMID: 38837608 Clinical Trial.
Editorial Comment.
Fang AM, Gregg JR. Fang AM, et al. Among authors: gregg jr. J Urol. 2024 Apr;211(4):563. doi: 10.1097/JU.0000000000003857. Epub 2024 Feb 1. J Urol. 2024. PMID: 38299558 No abstract available.
109 results